Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 24 | 2025 | 569 | 8.520 |
Why?
|
| Staphylococcus aureus | 22 | 2024 | 479 | 5.950 |
Why?
|
| Osteomyelitis | 10 | 2024 | 213 | 4.750 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 12 | 2025 | 229 | 3.930 |
Why?
|
| Bacteremia | 13 | 2025 | 428 | 3.740 |
Why?
|
| Streptococcal Infections | 6 | 2024 | 248 | 3.400 |
Why?
|
| Anti-Bacterial Agents | 24 | 2024 | 2553 | 2.980 |
Why?
|
| Arthritis, Infectious | 5 | 2025 | 67 | 2.740 |
Why?
|
| Soft Tissue Infections | 5 | 2024 | 91 | 2.140 |
Why?
|
| Microbial Sensitivity Tests | 14 | 2024 | 827 | 2.090 |
Why?
|
| Haemophilus Infections | 3 | 2025 | 97 | 1.720 |
Why?
|
| Haemophilus influenzae | 3 | 2025 | 135 | 1.710 |
Why?
|
| Sinusitis | 3 | 2024 | 119 | 1.660 |
Why?
|
| Streptococcus anginosus | 2 | 2024 | 10 | 1.510 |
Why?
|
| Otitis Media | 2 | 2024 | 90 | 1.430 |
Why?
|
| Child | 38 | 2025 | 25783 | 1.200 |
Why?
|
| Hospitals, Pediatric | 6 | 2025 | 780 | 1.170 |
Why?
|
| Vancomycin | 4 | 2023 | 222 | 1.170 |
Why?
|
| Child, Preschool | 24 | 2025 | 14735 | 1.120 |
Why?
|
| Texas | 14 | 2025 | 3632 | 1.060 |
Why?
|
| Penicillins | 3 | 2024 | 155 | 1.050 |
Why?
|
| Infant | 21 | 2025 | 13048 | 1.030 |
Why?
|
| Endocarditis, Bacterial | 3 | 2024 | 137 | 0.880 |
Why?
|
| Pneumococcal Infections | 2 | 2021 | 277 | 0.870 |
Why?
|
| Mastoiditis | 1 | 2024 | 33 | 0.840 |
Why?
|
| Brain Abscess | 1 | 2024 | 54 | 0.820 |
Why?
|
| Drug Monitoring | 1 | 2024 | 175 | 0.810 |
Why?
|
| Community-Acquired Infections | 4 | 2024 | 246 | 0.800 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 270 | 0.780 |
Why?
|
| Mupirocin | 2 | 2014 | 20 | 0.780 |
Why?
|
| Ascaridoidea | 1 | 2022 | 5 | 0.770 |
Why?
|
| Ascaridida Infections | 1 | 2022 | 5 | 0.770 |
Why?
|
| Anti-Infective Agents, Local | 3 | 2019 | 67 | 0.760 |
Why?
|
| Meningitis | 1 | 2022 | 100 | 0.740 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 277 | 0.720 |
Why?
|
| Pandemics | 3 | 2024 | 1186 | 0.700 |
Why?
|
| Retrospective Studies | 18 | 2025 | 17391 | 0.690 |
Why?
|
| Hospitalization | 4 | 2025 | 1902 | 0.680 |
Why?
|
| Humans | 46 | 2025 | 132201 | 0.680 |
Why?
|
| Streptococcus pyogenes | 3 | 2024 | 79 | 0.680 |
Why?
|
| Cefazolin | 1 | 2020 | 20 | 0.670 |
Why?
|
| Blood Culture | 1 | 2020 | 36 | 0.670 |
Why?
|
| Bacteria | 2 | 2021 | 522 | 0.650 |
Why?
|
| Thyroiditis, Suppurative | 1 | 2019 | 5 | 0.640 |
Why?
|
| Thyroid Crisis | 1 | 2019 | 6 | 0.630 |
Why?
|
| Candida tropicalis | 1 | 2019 | 17 | 0.630 |
Why?
|
| Echocardiography | 2 | 2024 | 1126 | 0.620 |
Why?
|
| Male | 28 | 2025 | 64979 | 0.610 |
Why?
|
| Adolescent | 17 | 2025 | 20557 | 0.600 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 946 | 0.600 |
Why?
|
| Streptococcus pneumoniae | 3 | 2025 | 381 | 0.600 |
Why?
|
| Multilocus Sequence Typing | 3 | 2024 | 62 | 0.590 |
Why?
|
| Incidence | 7 | 2025 | 3377 | 0.590 |
Why?
|
| Bone Diseases, Infectious | 1 | 2018 | 9 | 0.580 |
Why?
|
| Candidiasis | 1 | 2019 | 137 | 0.570 |
Why?
|
| Disease Management | 2 | 2021 | 565 | 0.560 |
Why?
|
| Chlorhexidine | 2 | 2017 | 47 | 0.550 |
Why?
|
| Bacterial Typing Techniques | 3 | 2021 | 104 | 0.520 |
Why?
|
| Female | 25 | 2025 | 70754 | 0.520 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 393 | 0.450 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2014 | 149 | 0.440 |
Why?
|
| Acute Disease | 4 | 2025 | 1163 | 0.420 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 40 | 0.420 |
Why?
|
| Staphylococcal Skin Infections | 3 | 2024 | 40 | 0.410 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 815 | 0.380 |
Why?
|
| Organ Transplantation | 1 | 2015 | 180 | 0.380 |
Why?
|
| Methicillin | 2 | 2023 | 43 | 0.370 |
Why?
|
| Infant, Newborn | 6 | 2025 | 8548 | 0.330 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 259 | 0.320 |
Why?
|
| HIV Infections | 2 | 2012 | 2050 | 0.320 |
Why?
|
| Urinary Bladder Diseases | 1 | 2008 | 34 | 0.280 |
Why?
|
| Clindamycin | 2 | 2022 | 41 | 0.280 |
Why?
|
| Urology | 1 | 2008 | 87 | 0.260 |
Why?
|
| Adenoma | 1 | 2008 | 146 | 0.260 |
Why?
|
| Prospective Studies | 5 | 2024 | 6569 | 0.240 |
Why?
|
| Kingella kingae | 1 | 2025 | 7 | 0.230 |
Why?
|
| Abscess | 2 | 2024 | 140 | 0.230 |
Why?
|
| Penicillin Resistance | 1 | 2024 | 81 | 0.220 |
Why?
|
| Cephalosporins | 2 | 2022 | 139 | 0.220 |
Why?
|
| Hospitals | 2 | 2022 | 439 | 0.220 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 450 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2025 | 178 | 0.210 |
Why?
|
| Cross Infection | 2 | 2019 | 343 | 0.210 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 749 | 0.200 |
Why?
|
| Outpatients | 1 | 2024 | 275 | 0.190 |
Why?
|
| beta-Lactamases | 1 | 2024 | 208 | 0.190 |
Why?
|
| Bacterial Infections | 1 | 2025 | 323 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 5410 | 0.180 |
Why?
|
| Kingella | 1 | 2021 | 1 | 0.180 |
Why?
|
| Comorbidity | 3 | 2014 | 1610 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2021 | 13028 | 0.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 45 | 0.170 |
Why?
|
| Heart Defects, Congenital | 2 | 2024 | 1866 | 0.170 |
Why?
|
| Metagenomics | 1 | 2022 | 106 | 0.170 |
Why?
|
| Ceftriaxone | 1 | 2021 | 69 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 162 | 0.170 |
Why?
|
| Streptococcus agalactiae | 1 | 2021 | 103 | 0.170 |
Why?
|
| Pott Puffy Tumor | 1 | 2020 | 4 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 45 | 0.160 |
Why?
|
| Central Nervous System Infections | 1 | 2020 | 22 | 0.160 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2019 | 93 | 0.160 |
Why?
|
| Hemoglobinopathies | 1 | 2019 | 17 | 0.160 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 494 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2021 | 699 | 0.150 |
Why?
|
| Coinfection | 1 | 2021 | 188 | 0.150 |
Why?
|
| Genes, MDR | 1 | 2019 | 6 | 0.150 |
Why?
|
| Enterobacter cloacae | 1 | 2018 | 13 | 0.150 |
Why?
|
| Thyroidectomy | 1 | 2019 | 102 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 264 | 0.150 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 79 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2013 | 382 | 0.140 |
Why?
|
| Genotype | 2 | 2019 | 2702 | 0.140 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 307 | 0.130 |
Why?
|
| Methicillin Resistance | 1 | 2017 | 118 | 0.130 |
Why?
|
| New Zealand | 1 | 2016 | 60 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2021 | 1233 | 0.130 |
Why?
|
| Age Factors | 2 | 2020 | 2920 | 0.130 |
Why?
|
| Sepsis | 2 | 2022 | 516 | 0.120 |
Why?
|
| Membrane Transport Proteins | 2 | 2019 | 181 | 0.120 |
Why?
|
| Australia | 1 | 2016 | 185 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1444 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 330 | 0.120 |
Why?
|
| United States | 2 | 2025 | 11675 | 0.110 |
Why?
|
| Prevalence | 2 | 2014 | 2663 | 0.110 |
Why?
|
| Genomics | 1 | 2022 | 1652 | 0.110 |
Why?
|
| Diterpenes | 1 | 2014 | 29 | 0.110 |
Why?
|
| Blood | 1 | 2014 | 103 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2018 | 1234 | 0.100 |
Why?
|
| Risk Factors | 2 | 2020 | 10944 | 0.090 |
Why?
|
| Bacterial Proteins | 2 | 2019 | 930 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 436 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 235 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 587 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3414 | 0.080 |
Why?
|
| Viral Load | 1 | 2012 | 408 | 0.080 |
Why?
|
| Serotyping | 1 | 2009 | 178 | 0.080 |
Why?
|
| Pharynx | 1 | 2019 | 66 | 0.080 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2019 | 117 | 0.070 |
Why?
|
| Nevus | 1 | 2008 | 35 | 0.070 |
Why?
|
| Adult | 3 | 2014 | 31600 | 0.070 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 324 | 0.070 |
Why?
|
| Young Adult | 2 | 2019 | 9965 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2019 | 1049 | 0.050 |
Why?
|
| Pelvis | 1 | 2024 | 74 | 0.050 |
Why?
|
| Clofazimine | 1 | 2021 | 7 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.050 |
Why?
|
| Animals | 1 | 2022 | 34842 | 0.040 |
Why?
|
| Glycopeptides | 1 | 2020 | 27 | 0.040 |
Why?
|
| beta-Lactams | 1 | 2020 | 56 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 247 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 106 | 0.040 |
Why?
|
| Salmonella | 1 | 2019 | 29 | 0.040 |
Why?
|
| Antiporters | 1 | 2019 | 35 | 0.040 |
Why?
|
| Enterococcus | 1 | 2019 | 31 | 0.040 |
Why?
|
| Staphylococcus | 1 | 2019 | 68 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 240 | 0.040 |
Why?
|
| Pediatrics | 1 | 2008 | 1210 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 189 | 0.040 |
Why?
|
| Catheter-Related Infections | 1 | 2020 | 137 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 2961 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 571 | 0.030 |
Why?
|
| Aged | 1 | 2014 | 21456 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1250 | 0.030 |
Why?
|
| Middle Aged | 1 | 2014 | 29007 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1723 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 802 | 0.020 |
Why?
|